Hagen M, et al. - In this investigation, researchers studied the impact of a risk-stratified disease-modifying anti-rheumatic drug (DMARD)–tapering algorithm based on multibiomarker disease activity (MBDA) score and anticitrullinated protein antibodies (ACPA) on the cost of direct treatment of patients with sustained remission rheumatoid arthritis (RA). In the prospective randomized RETRO study, the research was a posthoc retrospective analysis of direct treatment costs for 146 patients with RA in sustained remission tapering and stopping DMARD treatment. Data reported that the average reduction of DMARD costs per patient was €5358.83. According to findings, the combination of baseline MBDA score and ACPA status may allow risk stratification for successful DMARD tapering and cost-effective use of biologic DMARD in deep remission patients as defined by the 28-joint Disease Activity Score using erythrocyte sedimentation rate.